Background-Bilirubin, an effective antioxidant, shows a large variation in levels between individuals and has been positively associated with reduced cardiovascular disease risk. A major reason for the variability is a common promoter polymorphism, UGT1A1*28, which reduces the transcription of the enzyme that conjugates bilirubin, UDPglucuronosyltransferase 1A1. The aim of the study was to evaluate a possible protective effect of plasma bilirubin and the UGT1A1*28 polymorphism against myocardial infarction in a prospective case-referent setting. Methods and Results-Subjects (nϭ618) with a first-ever myocardial infarction (median event age, 60.5 years; median lag time, 3.5 years) and 1184 matched referents were studied. Plasma bilirubin was lower in cases versus referents. Despite a strong gene-dosage effect on bilirubin levels in both cases and referents, the UGT1A1*28 polymorphism did not influence the risk of myocardial infarction. Among multiple other variables, serum iron showed one of the strongest associations with bilirubin levels. Conclusions-We found no evidence for a protective effect of the UGT1A1*28 polymorphism against myocardial infarction and consequently neither for bilirubin. The lower bilirubin levels in cases might be caused by decreased production, increased degradation, or increased elimination. (Circ Cardiovasc Genet. 2010;3:340-347.)
B
ilirubin levels in plasma show a huge variation among individuals. Major causes of this variation are common variants in the UDP-glucuronosyltransferase 1A1 (UGT1A1) promoter region on chromosome 2q37. 1, 2 That region differentially regulates the expression of UGT1A1, the enzyme that conjugates bilirubin and thus enhances its elimination. Homozygosity for an insertion of a TA segment in the UGT1A1 promoter, for example, (TA) 7 /(TA) 7 instead of wild-type (TA) 6 /(TA) 6 , reduces the expression of UGT1A1 (EC 2.4.1.17) by 70%. 3 This homozygosity is the main reason for Mb Gilbert in whites.
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Multiple cross-sectional and retrospective 4 -12 and prospective [13] [14] [15] studies, including metaanalysis of such studies, 16 have reported an inverse relationship between bilirubin and cardiovascular disease. 17, 18 As to the (TA) 7 genotype, 2 retrospective studies have failed to find a risk association, 19, 20 whereas 1 study with prospective design found a strong association between (TA) 7 bearership and lower risk for cardiovascular disease, 21 whereas another prospective study found no evidence for lower risk for coronary heart disease. 22 The aim of our study was to evaluate how plasma bilirubin and the (TA) 7 genotype polymorphism influence the risk for first-ever myocardial infarction in a large, prospective, nested case-referent setting and to evaluate determinants of bilirubin levels.
Methods Study Cohort: Identification of Cases and Selection of Referents
This nested case-referent study was based on 3 subcohorts within the Northern Sweden Health and Disease Study Cohort (NSHDSC): the Västerbotten Intervention Project, the Northern Sweden WHO Monitoring of Trends and Cardiovascular Disease (MONICA) Study and the local Mammography Screening Project, which have been described in detail previously. 23 In the Västerbotten Intervention Project, all residents of Väster-botten County were invited to a free health examination on turning 30, 40, 50, and 60 years of age. The mean participation rate has been 57%. For the MONICA cohort 25-to 74-year-old subjects were invited to participate in health surveys during 1986, 1990, 1994, and 1999 . The mean participation rate was 77.2%. In total, 6952 subjects participated in the MONICA surveys. In the Mammary Screening Program, all women within 40 to 70 years of age were invited to undergo mammography every 2 or 3 years. The participation rate in screening was 85%, for donation of blood sample 57%. Participants in all 3 programs were invited to complete a standardized questionnaire and to donate a blood sample to be stored in the Northern Sweden Medical Research Bank. Subjects were interviewed by a trained nurse for all sorts of drugs used, which were coded according to the ATC system. Medication in this study was defined as use of any drug.
First-ever myocardial infarction cases (ICD-9 410, ICD-10 I21-3) between the ages of 25 and 64 years, in the counties of Västerbotten and Norrbotten between 1985 and 2000, were identified by linking the NSHDSC with the Northern Sweden MONICA registry using Swedish personal numbers as the linkage variable. Hospital records, general practitioner's reports, death certificates, and, when available, autopsy reports were screened to validate suspected events according to WHO MONICA criteria. Exclusion criteria for cases were previous myocardial infarction, stroke, or cancer diagnosis in the 5 years before, or stroke or cancer 1 year after diagnosis with myocardial infarction. Exclusion criteria for referents were myocardial infarction, stroke, cancer, or death before the time of diagnosis of the index case.
Within the NSHDSC, an early compilation of 77 cases and double referents was made. 24 From this material, DNA was available from 67 cases, but no plasma was available. In some 20 other cases, plasma was insufficient in volume or missing. Two subjects showed very high bilirubin levels (179 and 366 mol/L). These values were regarded as outliers and excluded from calculations.
For each case, 2 referents were selected, matched for sex, age, date of health survey, subcohort, and geographic area. The plasma specimens from cases and referents were analyzed in triplets of 1 case and 2 referents. To avoid systemic bias and interassay variability, the position within the triplet was randomly varied. The investigators and laboratory staff had no knowledge of case and referent status. The study protocol was approved by the Research Ethics Committee of Umeå University, Umeå.
Sample Collection and Laboratory Procedures
Collection of venous blood samples was performed using evacuated glass tubes containing heparin. The samples were centrifuged at 1500 g for 15 minutes to obtain heparinized plasma, which was subsequently stored at Ϫ80°C. In the Västerbotten Intervention Project and MONICA cohorts, samples were collected in the morning, after at least 4 hours of fasting. In the Mammography Screening Project cohort, samples were collected throughout the day. In this study, 72.6% of the subjects had fasted for more than 4 hours; 13.7% had fasted for less than 4 hours, and for 10.4% information about fasting status was missing (data not shown). We found no signs of heterogeneity in our material regarding bilirubin levels and genotype distributions (data not shown). Plasma bilirubin was analyzed on a Hitachi 911 multianalyzer with BIL-T kit Cat. No. 11489429216 (Roche Diagnostics GmbH, Mannheim, Germany). The intraassay coefficient of variation bilirubin was 3.63% at the level 18 mol/L and 3.72% at 88 mol/L. Before bilirubin analysis, the sample triplets had been frozen and thawed 5 times. Descriptions on other plasma analytes, that is, albumin, apolipoprotein A-I (ApoA1), apolipoprotein B (ApoB), cholesterol, cystatin C, high-sensitive CRP (hsCRP), homocysteine, iron, and total iron binding capacity are presented as supplementary information.
Genotyping was performed by fragment analysis using a slightly modified method previously described. 25 The primers for the PCR reaction were 5Ј-FAM-CAACAGTATCTTCCCAGC-3Ј and 5Ј-GTGTCCACGTGACACAGTCAAAC-3Ј (MWG-Biotech, Ebersberg, Germany). PCR reactions were run on a GeneAmp PCR System 9700: The 10-L reactions included 0.5 U AmpliTaq GOLD polymerase, 1ϫ Gene Amp buff II, 2.5 mmol/L MgCl 2 , 0,25 mmol/L dNTP, 335 nmol/L of each primer, and 15 ng DNA. Thermal cycling was carried out as follows: 95°C for 10 minutes followed by 10 cycles of 94°C for 15 seconds, 55°C for 15 seconds, and 72°C for 30 seconds. This was followed by 20 cycles of 89°C for 15 seconds, 55°C for 15 seconds, and 72°C for 30 seconds. Finally 72°C was applied for 10 minutes followed by a cooling step of 4°C. The PCR product was diluted 7 times with distilled water. For fragment analysis, 16 L GS500(-250)LIZ size standard was added to 1100 L HiDi-Formamide. To 10 L of the formamide-LIZ mixture, 1 L of the diluted PCR product was added. Samples were denatured at 95°C for 5 minutes, put on ice, and subsequently analyzed on an ABI 3730 xl automated DNA sequencer. Fragment analysis was performed using GeneMapper v3.0 software. The call rate for the analysis was 97.7% for referents and 96.6% for cases. All equipment and reagents, except for the primers, were from Applied Biosystems, Foster City, Calif.
Statistical Analysis
Hardy-Weinberg equilibrium was calculated using a java applet (http://www.kursus.kvl.dk/shares/vetgen/_Popgen/genetik/applets/ kitest.htm), where the calculations are based on the 2 test. Baseline characteristics for cases and referents were compared using 2 and Mann-Whitney U tests. Mann-Whitney U and KolmogorovSmirnov tests were used to evaluate differences in bilirubin levels, depending on fasting state. Plasma bilirubin quartile limits, based on referents, were calculated separately for men and women. Conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for disease: Bilirubin quartiles were coded 1 to 4 and treated as continuous linear variables when testing for trend. Genotypes were coded 1 to 2 (wild-type and heterozygote mutant versus homozygote mutant). Rare genotypes were coded as missing values in conditional logistic regression analysis. Missing values were treated as missing throughout the calculations. Regression analysis and analysis of variance was performed to find determinants of plasma bilirubin. In univariate analysis, all lifestyle and clinical variables, plasma analytes, and genotypes were included. Lifestyle factors that were nonsignificantly associated in univariate analysis were excluded from multivariate analysis, as were the derived plasma parameters transferrin iron saturation and ApoB/ ApoA1 ratio. All calculations were performed with SPSS version 17.0 (SPSS Inc. Chicago, Ill).
Results
The main characteristics of the study population including the distribution of UGT1A1 (TA) n sequences and plasma bilirubin levels are shown in Table 1 . The genotypes for both referents and cases were in Hardy-Weinberg equilibrium. In addition to the common (TA) 6 and (TA) 7 genotypes, we also found 4 individuals with the (TA) 5 genotype and 1 individual with (TA) 8 , which were excluded from further analysis. The proportion of fasting samples did not differ between cases and referents. A larger proportion of the cases had medication with 1 or more drugs, compared with the referents. Medicated individuals had significantly lower bilirubin levels compared with those without medication. There was no evidence for a difference in myocardial infarction risk between the different UGT1A1 genotypes: The (TA) 6 /(TA) 7 distributions did not diverge between cases and referents, and lag time and sex subgroup analyses likewise failed to reveal any significant associations (Table 2) . On the other hand, plasma bilirubin was lower in cases compared with referents, and analysis of risk associated with bilirubin level quartiles suggested a highly significant protective effect of the compound in univariate analysis (Table 3 ). In multivariate analysis, correcting for systolic blood pressure, smoking, ApoB/ApoA1, hsCRP, albumin and UGT1A1 genotypes, the odds ratios for bilirubin quartiles were no longer significant. Addition of medication of any drug to the models did not change the risk estimates. The (TA) 7 allele showed a strong gene-dosage effect on bilirubin levels both in referents and cases (Figure) . Notably, for each genotype, both in men and women the bilirubin levels were lower in cases compared with referents.
Multiple other variables were available in the test set that allowed a search for correlations with bilirubin levels (Tables  4 and 5 ). Using linear regression, in univariate analysis, (TA) 7 homozygosity, iron and transferrin iron saturation were positively associated with bilirubin levels in both cases and referents. Smoking, use of any drug, and albumin were negatively and cystatin C was positively associated with bilirubin levels in referents but not in cases. In multivariate analysis, there was a positive association between iron and cystatin C with bilirubin levels in cases and referents. (TA) 7 homozygosity was positively associated with bilirubin levels in referents only. Medication with any drug had a negative association with bilirubin levels in cases only. There was a Ekblom et al Bilirubin UGT1A1*28 and AMIsignificant interaction between medication and (TA) 7 homozygosity among cases (Pϭ0.035).
Discussion
We found a distinct relationship between the (TA) 7 genotype and high bilirubin levels in both referents and cases but no association with risk for myocardial infarction. Despite the fact that cases had lower bilirubin levels in plasma, our data suggest that bilirubin does not protect against myocardial infarction. Absence of information about UGT1A1 promoter polymorphism status in previous studies is the main reason for the misconception that bilirubin is a protective factor in itself. Our results suggest that the apparent increased risk in subjects with lower bilirubin levels might be due to confounding factors affecting both risk and bilirubin levels. In the Framingham Heart Study, 21 an apparent inverse association for risk of this polymorphism was seen for the combined group of coronary heart disease (fatal and nonfatal myocardial infarction, angina pectoris, or coronary insufficiency). However, in the 59 cases with myocardial infarction, no effect on risk was seen for this polymorphism. In the Rotterdam heart study, comprising 185 cases with myocardial infarction, there was no association with the (TA) 7 insertion. 22 We can thus confirm the earlier findings in our prospective cohort with 571 genotyped cases of myocardial infarction. Studies with different design and other atherosclerosis-associated end points, for example, intermittent claudication 17 and severity of coronary atherosclerosis, 18 likewise did not reveal any risk association with the UGT1A1 (TA) 7 polymorphism. Our findings are also supported by the results from multiple genome-wide association studies on cases with coronary artery disease and referents. 26 -33 In none of them was there a significant disease association with single nucleotide polymorphisms close to the UGT1A1 locus at chromosome 2q37.
As to the lower bilirubin levels in cases, the high susceptibility of the compound to oxidants might conceivably be significant. Atherosclerosis is generally regarded as an inflammatory disease with a strong participation of oxidant stress in the pathogenesis. 34 Oxidation of bilirubin partly yields biliverdin, which is rapidly reduced back to bilirubin, but irreversible oxidation to other products also occurs. 35 These compounds, which are thought to promote vasospasm, are rapidly excreted in the urine. 36 However, in the present study, there was no distinct correlation with the inflammation marker hsCRP (Tables 4 and 5 ). The strongest positive correlation found was with plasma level of the prooxidant iron, which if anything would be expected to lower bilirubin. A positive correlation between serum iron and bilirubin level has also previously been reported. 37 The metabolism in the liver of drugs and other xenobiotics as well as of many endogenous metabolites is induced by xenobiotic nuclear receptors. All 3 major such receptors (PXR, CaR, and AhR) influence UGT1A1 expression, which consequently is highly inducible. 38 Genetic, lifestyle, or environmental factors in cases might have induced higher rates of bilirubin conjugation. Multiple drugs are also likely to induce UGT1A1 expression. In addition, numerous drugs have been reported to interfere with and compete with various steps in bilirubin metabolism. Drug use might thus be a confounder and was in the present study found to be associ- ated with lower bilirubin levels both in referents and cases. The more common drug use among cases partially explains the lower bilirubin levels in individuals with later developing myocardial infarction. It is likely that a more common drug use also partially explains the lower bilirubin levels in cases in some previous cross-sectional/retrospective studies. In prospective studies with a relatively short sampling end point interval such as in the present study, drug use is also a likely confounder. (TA) 7 homozygosity was positively associated with higher bilirubin levels, and use of any drug was negatively associated. Among cases, drug use was more common in (TA) 7 homozygous subjects. This might explain why in the multivariate model, (TA) 7 homozygosity was no longer associated with bilirubin levels among cases. The key enzyme involved in bilirubin production is the inducible heme oxygenase 1 (HO-1) , and, to a lesser extent, the constitutive heme oxygenase 2 (HO-2). A recent study found a correlation between common promoter length polymorphisms of the HO-1 gene that influence transcription and bilirubin levels. 39 Notably HO-1 activity can be influenced by a variety of factors such as heme, endotoxin, heavy metals, oxidants, and hypoxia, 40 which might have differed between cases and referents. In addition, many drugs are known to induce HO-1, some of which are used for primary and secondary prevention of cardiovascular disease, such as statins and aspirin. 41 In our material, few persons were on lipid-lowering treatment (referents nϭ4, cases nϭ2) and/or platelet aggregation inhibitors, including aspirin (referents nϭ12, cases nϭ11). The intestinal flora can vary considerably between individuals and is suggested to influence human health. 42 It can influence the balance between bilirubin deconjugation and reabsorption versus reduction to urobilinogen species and elimination. 43, 44 Compounds formed by the flora might conceivably also influence UGT1A1 expression. The main strengths of the present study are the prospective design, a large sample size, and a well-defined study cohort of both men and women within an ethnically homogenous white population. The thorough registration of drug use is another important advantage. We were able to analyze both plasma bilirubin and the (TA) 7 genotype polymorphism. Owing to the abundance of information available for the study cohort, a number of potential confounders could be accounted for in this study. The interrelationship between cases and referents was not affected due to standardized procedures of thawing and analyzing the samples; all samples were treated equally and the cases and referents were also matched for time of blood sampling and health care unit where blood was drawn. A limitation of the study is that we were not able to account for silent cardiovascular events in the subjects before and after participation in the surveys. The study was also limited to a Northern Sweden population, but the UGT1A1 polymorphism allele frequencies found are similar to those reported in other studies on whites. 19 -20,22 In non-whites, other UGT1A1 polymorphisms are the main reasons for variability in bilirubin levels. 45 
Conclusion
Despite a gene-dose effect on bilirubin, the (TA) 7 genotype did not influence the risk. We found no convincing evidence that the (TA) 7 genotype or plasma bilirubin are protective factors for myocardial infarction. The lower bilirubin levels in cases might be caused by decreased production, increased degradation, or increased elimination.
